首页> 外文期刊>Hepato-gastroenterology. >Estrogen receptor beta variants mRNA expressions in gastric cancer tissues and association with clinicopathologic parameters.
【24h】

Estrogen receptor beta variants mRNA expressions in gastric cancer tissues and association with clinicopathologic parameters.

机译:胃癌组织中雌激素受体β变体mRNA的表达及其与临床病理参数的关系。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUNDS/AIMS: The aim of this study is to examine the expression of estrogen receptor beta-1, 2 ,5 in gastric cancer tissues and evaluate their correlation with clinicopathological features. METHODOLOGY: Real-time quantitative PCR assay was applied to detect the expression of estrogen receptor beta-1, 2, 5 mRNAs in 44 gastric cancer tissues and their paired normal tissues and correlate their mRNA levels with the clinicopathological properties of the tumors. 2(deltaCT) method was used to obtain the relative quantity of target mRNA expression. RESULTS: In almost all patients, estrogen receptor beta-1, 2, 5 mRNAs were expressed in gastric cancers and their matched normal tissues; however estrogen receptor beta-5 mRNA was not found in 8 normal gastric tissues. Estrogen receptor beta-5 had a much higher expression than estrogen receptor beta-1, 2 in gastric cancer tissues. Higher estrogen receptor beta-5 mRNAlevel was observed in gastric cancers than matched normal tissues (p = 0.001) and its increased expression was correlated with pTNM stage of the tumor (p = 0.032) and the lymph node metastasis (p = 0.026). Decreased mRNA level of estrogen receptor beta-1 was observed in gastric cancers compared to their matched normal tissues (p = 0.008). Estrogen receptor beta-1, 2 were not correlated with lymph node metastasis, gender, age, tumor size, tumor grade and pTNM stage (p > 0.05). CONCLUSIONS: This is the first study investigating the clinicopathologic role of estrogen receptor beta variants in gastric cancer. Our study shows that estrogen receptor beta-5 is the most important factor for gastric cancer development and progression among the three estrogen receptor beta variants.
机译:背景/目的:本研究的目的是检查胃癌组织中雌激素受体β-1、2、5的表达,并评估其与临床病理特征的相关性。方法:采用实时荧光定量PCR检测44种胃癌组织及其配对正常组织中雌激素受体β-1、2、5 mRNA的表达,并将其mRNA水平与肿瘤的临床病理特征相关联。 2(deltaCT)方法用于获得目标mRNA表达的相对数量。结果:在几乎所有患者中,胃癌及其匹配的正常组织中均表达雌激素受体β-1、2、5 mRNA。然而,在8个正常胃组织中未发现雌激素受体β-5mRNA。在胃癌组织中,雌激素受体β-5的表达比雌激素受体β-1、2高得多。在胃癌中观察到比匹配的正常组织更高的雌激素受体β-5mRNA水平(p = 0.001),其表达增加与肿瘤的pTNM分期(p = 0.032)和淋巴结转移(p = 0.026)相关。与匹配的正常组织相比,胃癌中雌激素受体β-1的mRNA水平降低(p = 0.008)。雌激素受体β-1、2与淋巴结转移,性别,年龄,肿瘤大小,肿瘤等级和pTNM分期无关(p> 0.05)。结论:这是第一项研究雌激素受体β变体在胃癌中的临床病理作用的研究。我们的研究表明,雌激素受体β-5是三种雌激素受体β变异体中胃癌发生和发展的最重要因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号